Global Cetuximab Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cetuximab Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.
Cetuximab report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cetuximab market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Head and Neck Cancer and Metastatic Colorectal Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cetuximab industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cetuximab key manufacturers include Eli Lilly and Merck etc. Eli Lilly, Merck, are top 3 players and held % sales share in total in 2022.
Cetuximab can be divided into 100 mg/50 mL Injection and 200 mg/100 mL Injection, etc. 100 mg/50 mL Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Cetuximab is widely used in various fields, such as Head and Neck Cancer and Metastatic Colorectal Cancer, etc. Head and Neck Cancer provides greatest supports to the Cetuximab industry development. In 2022, global % sales of Cetuximab went into Head and Neck Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cetuximab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Eli Lilly
Merck
Segment by Type
100 mg/50 mL Injection
200 mg/100 mL Injection
Head and Neck Cancer
Metastatic Colorectal Cancer
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cetuximab market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cetuximab, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cetuximab industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cetuximab in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cetuximab introduction, etc. Cetuximab Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cetuximab market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Cetuximab report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cetuximab market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Head and Neck Cancer and Metastatic Colorectal Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cetuximab industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Cetuximab key manufacturers include Eli Lilly and Merck etc. Eli Lilly, Merck, are top 3 players and held % sales share in total in 2022.
Cetuximab can be divided into 100 mg/50 mL Injection and 200 mg/100 mL Injection, etc. 100 mg/50 mL Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Cetuximab is widely used in various fields, such as Head and Neck Cancer and Metastatic Colorectal Cancer, etc. Head and Neck Cancer provides greatest supports to the Cetuximab industry development. In 2022, global % sales of Cetuximab went into Head and Neck Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cetuximab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Eli Lilly
Merck
Segment by Type
100 mg/50 mL Injection
200 mg/100 mL Injection
Segment by Application
Head and Neck Cancer
Metastatic Colorectal Cancer
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cetuximab market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cetuximab, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cetuximab industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cetuximab in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cetuximab introduction, etc. Cetuximab Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cetuximab market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices